Active Needle Technology and MT.Derm sign licensing agreement.

Active Needle Technology (ANT), a UK based ultrasonic needles company and MT.Derm, a market leading tattoo manufacturer today announce a licensing deal in the area of low pain tattooing. ANT’s patented high frequency needle technology has been shown to reduce both the pain and swelling associated with tattooing.

Ian Quirk, ANT’s CEO and co-inventor of the technology said “We’re delighted to be working with MT.Derm to produce the world’s first truly low pain tattooing product. Ultrasonic action bestows a wide range of important properties from the low pain of needle insertion to enhanced visibility – vital in many needle placement applications in medicine. Along with our growing portfolio of innovative medical devices, the opportunity to collaborate with an innovative and successful company such as MT.Derm opens an important adjacent market and further demonstrates the potential of ultrasonic needles.”

MT.Derm will develop and market what is expected to be a revolution in tattooing: low pain, low trauma tattoos.

Active Needle Technology LTD, located on Culham Science Centre in Oxfordshire, was founded in 2016. Its aim is to bring the benefits of ultrasonic needles to a range of markets centred around healthcare. The company’s first CE marked product; the BrightLineTM core biopsy needle, is the first of many planned medical devices for use where ultrasound scans and the need for accurate needle placement overlap. The tattoo product was developed initially with support from InnovateUK.